Cargando…
Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study
AIMS: Dipeptidyl peptidase-4, a transmembrane glycoprotein expressed in various cell types, serves as a co-stimulator molecule to influence immune response. This study aimed to investigate associations between DPP-4 inhibitors and risk of autoimmune disorders in patients with type 2 diabetes mellitu...
Autores principales: | Chen, Yi-Chuan, Chen, Tien-Hsing, Sun, Chi-Chin, Chen, Jau-Yuan, Chang, Shy-Shin, Yeung, Ling, Tsai, Yi-Wen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173685/ https://www.ncbi.nlm.nih.gov/pubmed/32318876 http://dx.doi.org/10.1007/s00592-020-01533-5 |
Ejemplares similares
-
Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
por: Kang, Eugene Yu-Chuan, et al.
Publicado: (2021) -
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
por: Chang, Chia-Yu, et al.
Publicado: (2017) -
Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan
por: Hsu, Wei-Hao, et al.
Publicado: (2021) -
Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
por: Chen, Kuan-Chan, et al.
Publicado: (2020) -
Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
por: Huang, Jie, et al.
Publicado: (2022)